SymBio Pharmaceuticals Limited
Stock Price Chart
2026/10/07 19:11 UpdatedPrice Trend
2026/10/07 19:11 UpdatedPrice & Trading Details
2026/10/07 19:11 UpdatedPRICE
TRADING
Earnings Calendar
Updated 2026/10/01Shareholder Composition
Updated 2026/10/01Financial Performance
2026/10/04 UpdatedRevenue & Profit
Margins
Cash Flow
Financial Health
| 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | ¥10,008M | ¥5,590M | ¥2,453M | ¥1,308M |
| Gross Profit | ¥7,600M | ¥4,411M | ¥1,873M | ¥947M |
| Operating Income | ¥1,964M | -¥812M | -¥3,877M | -¥4,441M |
| Pretax Income | ¥1,964M | -¥812M | -¥3,807M | -¥4,709M |
| Net Income | ¥1,179M | -¥1,963M | -¥3,833M | -¥4,776M |
| EPS | ¥29.77 | -¥49.19 | -¥85.00 | -¥95.12 |
| Operating Margin | 19.62% | -14.52% | -158.06% | -339.59% |
| Balance Sheet | ||||
| Total Assets | ¥10,433M | ¥8,170M | ¥4,968M | ¥3,867M |
| Total Equity | ¥8,506M | ¥7,210M | ¥4,198M | ¥1,272M |
| Total Liabilities | ¥1,927M | ¥960M | ¥771M | ¥2,595M |
| Cash | ¥6,283M | ¥6,517M | ¥3,964M | ¥2,884M |
| Interest-bearing Debt | - | - | ¥0M | ¥1,983M |
| Equity Ratio | 81.53% | 88.25% | 84.49% | 32.89% |
| D/E Ratio | 0.00 | 0.00 | 0.00 | 1.56 |
| Cash Flow | ||||
| Operating CF | ¥1,614M | -¥195M | -¥3,417M | -¥4,576M |
| Investing CF | -¥47M | -¥377M | -¥4M | -¥76M |
| Financing CF | ¥628M | ¥680M | ¥708M | ¥3,622M |
| Free CF | ¥1,567M | -¥427M | -¥3,463M | -¥4,658M |
| Efficiency | ||||
| ROE | 13.86% | -27.22% | -91.33% | -375.48% |
| ROA | 11.30% | -24.02% | -77.16% | -123.50% |
Latest IR Information
-
Initiation of Consultations for Conditional Marketing Authorization (CMA) in the UK for Brincidofovir (BCV)
Consultations with the MHRA have begun for BCV to obtain UK CMA. The company will concurrently complete the global Phase III trial as quickly as possible to accelerate access to global markets. Impact on the fiscal year ending December 2026...
Read more -
Notice Regarding the Monthly Exercise Status of the 70th and 71st Stock Acquisition Rights Issued by Third-Party Allotment (with Exercise Price Adjustment Clause)
Published the monthly exercise status for September 2026 of the 70th and 71st stock acquisition rights. Number of shares granted: 4,300,000 shares; number of rights actually exercised in September: 43,000; ratio to total issued: 9.0%; unexercised rights: 437,000; exercise restriction:...
Read more -
Exclusive Global License for BCV Obtained for MS – Licensing Agreement for development with U.S. Department of Health and Human Services
Entered into an exclusive global license for BCV as a treatment and preventive for MS via NIH/NINDS. Also reports CRADA extension and development progress toward clinical trials. States no impact on consolidated results for the fiscal year ending December 2026.
Read more -
Notice on the Completion of Payment for the 2nd Unsecured Ordinary Bond (Private Placement)
Total amount of the 2nd unsecured ordinary bond (private placement) issued and paid in is 100,000,000 yen. Maturity date is September 3, 2029, interest rate 0%, late surcharge 20%. Issuer is EVO FUND, with related transactions involving new share subscription...
Read more -
Notice regarding the completion of the acquisition and cancellation of the 58th, 66th and 67th stock acquisition rights, and the payment of the issue price for the 70th and 71st stock acquisition rights (with exercise price adjustment clause) issued to a third party
Acquisition and cancellation of stock acquisition rights completed; allocation of the 70th and 71st stock acquisition rights to EVO FUND. Total issue amount: 2,880,000 yen; potential shares: 96,000,000 shares; exercise price adjustment clause; exercise period: 2026/09/03–2029/09/03. Estimated funds raised: 6,768,880,000...
Read more
Latest News (5 items)
Company Information
About
SymBio Pharmaceuticals Limited engages in the and development, manufacturing and sales of pharmaceuticals and other related operations in Japan and internationally. It offers SyB V-1901, an antiviral drug for post-transplant infections, blood cancers and solid tumors, and neurodegenerative diseases; SyB L-1701, an RTD liquid formulation; and SyB L-1702, an RI administration under the TREAKISYM name. The company was incorporated in 2005 and is based in Minato, Japan.
